Literature DB >> 10815989

Characterization of distinct Gal:3-O-sulfotransferase activities in human tumor epithelial cell lines and of calf lymph node GlcNAc : 6-O-sulfotransferase activity.

E V Chandrasekaran1, R K Jain, J M Rhodes, R Chawda, C Piskorz, K L Matta.   

Abstract

We found earlier in human breast and colon tumors, an augmented level of Gal : 3-O-sulfotransferase activities showing, respectively, an acceptor preference to blood group T-hapten (Group A enzymes) or Galbeta1,4GlcNAc (Group B enzymes) on the mucin Core 2 structure [Chandrasekaran EV, Jain RK, Vig R, and Matta KL (1997) Glycobiology 7: 753-68]. The present study reports these enzyme activities in human tumor cell lines and additional tumor specimens. The human colon tumor epithelial cell lines, akin to their parent tumors, express Group B enzyme activity. The acceptor specificity and kinetic properties, such as divalent metal ion activation and pH dependent activity profile, of the colon cancer line LS180 enzyme activity are identical to those of colon tissue specimens. Consistent with breast tumor specimens, the Group A enzyme activity is present in human breast tumor epithelial cell lines, with some exceptions. The Gal : 3-O-sulfotransferases show specific binding to Aleuria aurantia lectin, suggesting the presence of asparagine linked carbohydrate chains containing an inner core alpha1,6-fucosyl residue on these enzymes. Calf lymph nodes contain GlcNAc : 6-O-sulfotransferase as well as Group A Gal : 3-O-sulfotransferase activities, which differ in pH dependent profiles, pH optima (7.6 and 7.0, respectively) and the influence of Mn2+.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10815989     DOI: 10.1023/a:1007074005371

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  42 in total

1.  Selectin inhibition: synthesis and evaluation of novel sialylated, sulfated and fucosylated oligosaccharides, including the major capping group of GlyCAM-1.

Authors:  A Koenig; R Jain; R Vig; K E Norgard-Sumnicht; K L Matta; A Varki
Journal:  Glycobiology       Date:  1997-02       Impact factor: 4.313

2.  Sulfated lewis X determinants as a major structural motif in glycans from LS174T-HM7 human colon carcinoma mucin.

Authors:  C Capon; J M Wieruszeski; J Lemoine; J C Byrd; H Leffler; Y S Kim
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

3.  Defective acidification of intracellular organelles in cystic fibrosis.

Authors:  J Barasch; B Kiss; A Prince; L Saiman; D Gruenert; Q al-Awqati
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

4.  Structures of sulfated oligosaccharides isolated from the respiratory mucins of a non-secretor (O, Le(a + b -)) patient suffering from chronic bronchitis.

Authors:  J M Lo-Guidice; H Herz; G Lamblin; Y Plancke; P Roussel; M Lhermitte
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

5.  Novel sulfated ligands for the cell adhesion molecule E-selectin revealed by the neoglycolipid technology among O-linked oligosaccharides on an ovarian cystadenoma glycoprotein.

Authors:  C T Yuen; A M Lawson; W Chai; M Larkin; M S Stoll; A C Stuart; F X Sullivan; T J Ahern; T Feizi
Journal:  Biochemistry       Date:  1992-09-29       Impact factor: 3.162

6.  Expression of blood group Lewis b determinant from Lewis a: association of this novel alpha (1,2)-L-fucosylating activity with the Lewis type alpha (1,3/4)-L-fucosyltransferase.

Authors:  E V Chandrasekaran; R K Jain; J M Rhodes; C A Srnka; R D Larsen; K L Matta
Journal:  Biochemistry       Date:  1995-04-11       Impact factor: 3.162

7.  Specificity analysis of three clonal and five non-clonal alpha 1,3-L-fucosyltransferases with sulfated, sialylated, or fucosylated synthetic carbohydrates as acceptors in relation to the assembly of 3'-sialyl-6'-sulfo Lewis x (the L-selectin ligand) and related complex structures.

Authors:  E V Chandrasekaran; R K Jain; R D Larsen; K Wlasichuk; R A DiCioccio; K L Matta
Journal:  Biochemistry       Date:  1996-07-09       Impact factor: 3.162

8.  Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria aurantia lectin.

Authors:  K Yamashita; N Kochibe; T Ohkura; I Ueda; A Kobata
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

9.  E-selectin binding by pancreatic tumor cells is inhibited by cancer sera.

Authors:  T Sawada; J J Ho; Y S Chung; M Sowa; Y S Kim
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

10.  Structure of the O-glycans in GlyCAM-1, an endothelial-derived ligand for L-selectin.

Authors:  S Hemmerich; H Leffler; S D Rosen
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

View more
  4 in total

1.  Mammalian sialyltransferase ST3Gal-II: its exchange sialylation catalytic properties allow labeling of sialyl residues in mucin-type sialylated glycoproteins and specific gangliosides.

Authors:  E V Chandrasekaran; Jun Xue; Jie Xia; Robert D Locke; Shilpa A Patil; Sriram Neelamegham; Khushi L Matta
Journal:  Biochemistry       Date:  2011-10-13       Impact factor: 3.162

2.  Distinct substrate specificities of human GlcNAc-6-sulfotransferases revealed by mass spectrometry-based sulfoglycomic analysis.

Authors:  Shin-Yi Yu; Cheng-Te Hsiao; Mineko Izawa; Akiko Yusa; Hiroji Ishida; Shigeo Nakamura; Hirokazu Yagi; Reiji Kannagi; Kay-Hooi Khoo
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

3.  GAL3ST2 from mammary gland epithelial cells affects differentiation of 3T3-L1 preadipocytes.

Authors:  L N Guerra; C Suarez; D Soto; A Schiappacasse; D Sapochnik; P Sacca; G Piwien-Pilipuk; B Peral; J C Calvo
Journal:  Clin Transl Oncol       Date:  2014-12-23       Impact factor: 3.405

4.  Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II.

Authors:  E V Chandrasekaran; Jun Xue; Jie Xia; Robert D Locke; Shilpa A Patil; Sriram Neelamegham; Khushi L Matta
Journal:  J Proteome Res       Date:  2012-02-29       Impact factor: 4.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.